Sara Schaefer discusses the history, inner workings, and vision of the International Parkinson and Movement Disorder Society with current MDS President Francisco Cardoso.
Read MoreDeep brain stimulation (DBS) has long been considered a risky procedure for people with Parkinson’s disease and cognitive impairment. In this interview, Dr. Miocinovic presents real-world data, showing that DBS might be safe and useful in carefully selected patients with moderate cognitive impairment. Read the article.
Read MoreIn this History of Movement Disorders Special Episode, Prof. Tiago Outeiro interviews Prof. Maria Grazia Spillantini about integral work involved in discovering the role alpha-synuclein plays in the development of Lewy bodies. She discusses where the field is now and what questions young researchers should start asking.
Read MoreIn this special Hot Topics episode, Dr. Filip Scheperjans discusses what we know and what we don’t yet know about the gut microbiome in Parkinson’s disease, theories of influencing pathways within the gut-brain axis, and future directions for exploring and altering the gut microbiome in this patient population to impact disease.
Read MoreSara Schaefer discusses with Dr. Eduardo de Pablo-Fernandez his recent paper in Movement Disorders providing retrospective pathological validation of the 2022 MDS MSA Criteria using specimens from the Queens Square Brain Bank. Read the article.
Read MoreIn this paper, Dr. Vrustangkumar Shah and colleagues evaluated gait in patients with Parkinson’s disease in the lab and in real life, with and without levodopa through wearable sensors. Some measures are able to discriminate fallers from non-fallers in PD. Read the article.
Read MoreTwo clinical trials with antibodies targeting alpha synuclein in early Parkinson’s disease have been published in the New England Journal of Medicine. Anthony Lang and Gennaro Pagano, the first authors of the articles share the results and discuss the possible future perspectives with the MDS Podcast editor, Michele Matarazzo. Read the prasinezumab article. Read the…
Read MoreIn part 5 of the Dystonia Special Series, Dr. Francesca Morgante interviews Dr. Jill Ostrem about current and future approaches to treatment of dystonia.
Read MoreIn part 4 of the Dystonia Special Series, Dr. Francesca Morgante interviews Dr. Anna Sadnicka on the neural roots of dystonia.
Read MoreDr. Matarazzo interviews Émeline Courtois about the recently published article on machine learning approach to discover marketed drugs that could have an impact on the development of Parkinson’s disease. Interestingly, furosemide and adrenergic drugs showed a potential protective effect in this very large cohort. Journal CME is available until January 19, 2024 Read the article.
Read More